Flowvium
एक्सप्लोरर पर वापस जाएं

AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

शेयर करें:
⇄ Compare

उत्पाद और राजस्व

उत्पाद राजस्व हिस्सा

राजस्व विवरण ($56.3B)

स्थैतिक डेटा (लाइव वित्तीय लोड हो रहे हैं…)

Immunology (45%)
Aesthetics/Neuroscience (25%)
Oncology (15%)
Eye Care & Other (15%)

सेगमेंट संरचना और प्रमुख ग्राहक

उत्पाद विवरण

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

आपूर्ति श्रृंखला संबंध

प्रतिस्पर्धी

Eli Lilly and Company

Immunology and oncology drugs

प्रभाव: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

प्रभाव: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

प्रभाव: Major pharma rival

व्यापक एवं बाजार संदर्भ

제약 / 바이오क्षेत्र समाचार

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

आगामी उत्प्रेरक

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

संस्थागत संकेत

संस्थाकार्रवाईमूल्यतिमाहीफाइलिंग तिथि
BlackRockaccumulating$717M2024.062024-08-13↑
BlackRockreducing$272M2024.062024-08-13↓
BlackRockreducing$277M2024.062024-08-13↓
BlackRockreducing$21M2024.062024-08-13↓
BlackRockreducing$43M2024.062024-08-13↓
BlackRockaccumulating$507M2024.062024-08-13↑
BlackRockaccumulating$571M2024.062024-08-13↑
BlackRockaccumulating$8.8B2024.062024-08-13↑
BlackRockaccumulating$6.6B2024.062024-08-13↑
BlackRockaccumulating$563M2024.062024-08-13↑
BlackRockaccumulating$923M2024.062024-08-13↑
BlackRockreducing$346M2024.062024-08-13↓
BlackRockaccumulating$608M2024.062024-08-13↑
BlackRockreducing$6M2024.062024-08-13↓
BlackRockaccumulating$1.9B2024.062024-08-13↑
BlackRockreducing$83M2024.062024-08-13↓
BlackRockreducing$30M2024.062024-08-13↓
BlackRockaccumulating$643M2024.062024-08-13↑
BlackRockreducing$64M2024.062024-08-13↓
BlackRockreducing$11M2024.062024-08-13↓
BlackRockreducing$15M2024.062024-08-13↓
BlackRockreducing$399K2024.062024-08-13↓
BlackRockaccumulating$460M2024.062024-08-13↑
Vanguard Groupaccumulating$2.3B2025.122026-01-29↑
Vanguard Groupaccumulating$193M2025.122026-01-29↑
Vanguard Groupaccumulating$37.1B2025.122026-01-29↑
Vanguard Groupaccumulating$754M2025.122026-01-29↑
Vanguard Groupaccumulating$882M2025.122026-01-29↑
Vanguard Groupaccumulating$9M2025.122026-01-29↑
State Streetaccumulating$18.5B2025.122026-02-13↑
Wellington Managementaccumulating$3.1B2025.122026-02-17↑
Wellington Managementaccumulating$65M2025.122026-02-17↑
Wellington Managementreducing$32M2025.122026-02-17↓
Wellington Managementreducing$46M2025.122026-02-17↓
Wellington Managementreducing$24M2025.122026-02-17↓
Wellington Managementreducing$42M2025.122026-02-17↓
Wellington Managementreducing$37M2025.122026-02-17↓
Wellington Managementreducing$5M2025.122026-02-17↓
Wellington Managementaccumulating$93M2025.122026-02-17↑
FMR (Fidelity)accumulating$3.8B2025.122026-02-17↑
FMR (Fidelity)accumulating$280M2025.122026-02-17↑
FMR (Fidelity)accumulating$822M2025.122026-02-17↑
FMR (Fidelity)accumulating$41M2025.122026-02-17↑
FMR (Fidelity)accumulating$218M2025.122026-02-17↑
FMR (Fidelity)accumulating$25M2025.122026-02-17↑

ताज़ा खबर

समाचार लोड हो रहा है...

AI विश्लेषण

AbbVie Inc. का AI आपूर्ति श्रृंखला विश्लेषण प्राप्त करने के लिए "AI विश्लेषण प्राप्त करें" पर क्लिक करें।

कंपनी जानकारी

मुख्यालय

North Chicago, Illinois, USA

स्थापना

2013

कर्मचारी

50,000+

वेबसाइट

abbvie.com

क्षेत्र अवलोकन — 제약 / 바이오

क्षेत्र समाचार

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

मुख्य विषय

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

आगामी उत्प्रेरक

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정